{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:56:14Z","timestamp":1756572974108,"version":"3.40.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00277-021-04471-6","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T09:03:42Z","timestamp":1614848622000},"page":"1195-1202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients"],"prefix":"10.1007","volume":"100","author":[{"given":"Andrius","family":"Zucenka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazimieras","family":"Maneikis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birute","family":"Pugaciute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugne","family":"Ringeleviciute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austeja","family":"Dapkeviciute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linas","family":"Davainis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoda","family":"Daukelaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina","family":"Burzdikaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vytautas","family":"Staras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laimonas","family":"Griskevicius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"4471_CR1","doi-asserted-by":"publisher","unstructured":"Ferrara F, Lessi F, Vitagliano O, Birkenghi E, Rossi G (2019) Current therapeutic results and treatment options for older patients with relapsed acute myeloid leukemia. Cancers (Basel) 11(2):224. https:\/\/doi.org\/10.3390\/cancers11020224","DOI":"10.3390\/cancers11020224"},{"issue":"8","key":"4471_CR2","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40266-015-0285-6","volume":"32","author":"JC Bryan","year":"2015","unstructured":"Bryan JC, Jabbour EJ (2015) Management of relapsed\/refractory acute myeloid leukemia in the elderly: current strategies and developments. Drugs Aging 32(8):623\u2013637","journal-title":"Drugs Aging"},{"issue":"10","key":"4471_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-020-00376-1","volume":"10","author":"N Daver","year":"2020","unstructured":"Daver N, Wei AH, Pollyea DA, Fathi AT, Vyas P, DiNardo CD (2020) New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J 10(10):1\u201312","journal-title":"Blood Cancer J"},{"issue":"2","key":"4471_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41571-018-0156-2","volume":"16","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Perl AE (2019) Advances in patient care through increasingly individualized therapy. Nat Rev Clin Oncol 16(2):73\u201374","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"4471_CR5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/14656566.2020.1713094","volume":"21","author":"X Thomas","year":"2020","unstructured":"Thomas X, Heiblig M (2020) An evaluation of glasdegib for the treatment of acute myelogenous leukemia. Expert Opin Pharmacother 21(5):523\u2013530","journal-title":"Expert Opin Pharmacother"},{"key":"4471_CR6","doi-asserted-by":"publisher","unstructured":"Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW (2016) Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers 8(2):22. https:\/\/doi.org\/10.3390\/cancers8020022","DOI":"10.3390\/cancers8020022"},{"key":"4471_CR7","doi-asserted-by":"publisher","unstructured":"Terao T, Minami Y (2019) Targeting hedgehog (Hh) pathway for the acute myeloid leukemia treatment. Cells 8(4):312. https:\/\/doi.org\/10.3390\/cells8040312","DOI":"10.3390\/cells8040312"},{"issue":"20","key":"4471_CR8","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1158\/1078-0432.CCR-19-0365","volume":"25","author":"KJ Norsworthy","year":"2019","unstructured":"Norsworthy KJ, By K, Subramaniam S, Zhuang L, Valle PLD, Przepiorka D et al (2019) FDA approval summary: glasdegib for newly diagnosed acute myeloid leukemia. Clin Cancer Res 25(20):6021\u20136025","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4471_CR9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","volume":"33","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Montesinos P, Pollyea DA, DesJardins P, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O\u2019Connell A, Chan G, Heuser M (2019) Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 33(2):379\u2013389","journal-title":"Leukemia."},{"issue":"11","key":"4471_CR10","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/ajh.25238","volume":"93","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, Pollyea DA, Sekeres MA, Robak T, Ma WW, Zeremski M, Naveed Shaik M, Douglas Laird A, O'Connell A, Chan G, Schroeder MA (2018) Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results. Am J Hematol 93(11):1301\u20131310","journal-title":"Am J Hematol"},{"issue":"31","key":"4471_CR11","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.2217\/fon-2019-0373","volume":"15","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Dombret H, Merchant A, Tauchi T, DiRienzo CG, Sleight B et al (2019) Glasdegib plus intensive\/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. Future Oncol 15(31):3531\u20133545","journal-title":"Future Oncol"},{"issue":"4","key":"4471_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447","journal-title":"Blood"},{"key":"4471_CR13","doi-asserted-by":"publisher","unstructured":"Tavares M, Chacim S, Mariz JM (2020) Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome. Ann Hematol [cited 2021 Jan 11]; Available from: https:\/\/doi.org\/10.1007\/s00277-020-04291-0","DOI":"10.1007\/s00277-020-04291-0"},{"key":"4471_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.leukres.2019.03.008","volume":"81","author":"DA Sallman","year":"2019","unstructured":"Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH et al (2019) A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). Leuk Res 81:56\u201361","journal-title":"Leuk Res"},{"issue":"1","key":"4471_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-020-00929-8","volume":"13","author":"JE Cortes","year":"2020","unstructured":"Cortes JE, Heidel FH, Fiedler W, Smith BD, Robak T, Montesinos P, Candoni A, Leber B, Sekeres MA, Pollyea DA, Ferdinand R, Ma WW, O\u2019Brien T, O\u2019Connell A, Chan G, Heuser M (2020) Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. J Hematol Oncol 13(1):92","journal-title":"J Hematol Oncol"},{"issue":"8","key":"4471_CR16","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3324\/haematol.2019.222794","volume":"104","author":"AS Kubasch","year":"2019","unstructured":"Kubasch AS, Platzbecker U (2019) The wolf of hypomethylating agent failure: what comes next? Haematologica. 104(8):1505\u20131508","journal-title":"Haematologica."},{"issue":"24","key":"4471_CR17","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","volume":"29","author":"T Pr\u00e9bet","year":"2011","unstructured":"Pr\u00e9bet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, Dreyfus F, Rauzy OB, Recher C, Ad\u00e8s L, Quesnel B, Beach CL, Fenaux P, Vey N (2011) Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 29(24):3322\u20133327","journal-title":"J Clin Oncol"},{"key":"4471_CR18","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1016\/j.clml.2015.03.010","volume":"15","author":"RS Komrokji","year":"2015","unstructured":"Komrokji RS (2015) Treatment of higher-risk myelodysplastic syndromes after failure of hypomethylating agents. Clin Lymphoma Myeloma Leuk 15:S56\u2013S59","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4471_CR19","doi-asserted-by":"publisher","unstructured":"Zucenka A, Pileckyte R, Trociukas I, Peceliunas V, Vaitekenaite V, Maneikis K, et al. Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax-based salvage therapies. Eur J Haematol [cited 2020 Nov 2];n\/a(n\/a). Available from: https:\/\/doi.org\/10.1111\/ejh.13527","DOI":"10.1111\/ejh.13527"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04471-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04471-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04471-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T04:49:14Z","timestamp":1744087754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04471-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["4471"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04471-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2021,3,4]]},"assertion":[{"value":"29 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the Vilnius Regional Biomedical Research Ethics Committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All procedures followed were in accordance with the ethical standards of the Vilnius Regional Biomedical Research Ethics Committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Informed consent was obtained from all patients for being included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}